* Orgenesis Inc ORGS.OQ ORGS.O is expected to show a rise in
quarterly revenue when it reports results on November 3
(estimated).
* The Germantown, Maryland-based company is expected to report
a 420.5% increase in revenue to $9 million from $1.73 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data.
* Refinitiv's mean analyst estimate for Orgenesis Inc is for a
loss of 3 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Orgenesis Inc
is $9, about 46.6% above its last closing price of $4.81.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 302021 -0.23 -0.23 -0.11 Beat 52.2
Mar. 312021 -0.26 -0.26 0.01 Beat 103.8
Mar. 312020 -0.20 -0.39 Missed -95
Dec. 312019 -0.27 -0.42 Missed -55.6
Sep. 302019 -0.28 -0.28 -0.44 Missed -57.1
This summary was machine generated November 1 at 18:32 GMT. All
figures in US dollars unless otherwise stated